secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116364
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient
--------------------------------------------------------------------------------

- Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.
- First lymphoma patient treated with MT-601 in Phase 1 APOLLO trial achieved complete metabolic response after failing CAR T therapy.
- MT-401 (zedenoleucel) received Orphan Drug Designation from EMA for AML; clinical trial for MT-401 off-the-shelf expected in 2024.
- Cash and cash equivalents of $17.5M as of September 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/0001104659-23-116364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/tm2330322d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer